Obstetric Labour, Premature
Conditions
Keywords
Spontaneous Preterm Labor, GSK221149, Retosiban
Brief summary
The study's primary objective is to demonstrate the superiority of retosiban to prolong pregnancy and improve neonatal outcomes compared with placebo. It is a Phase III, randomized, double-blind, parallel-group, multicenter study and will be conducted in approximately 900 females, aged 12 to 45 years, with an uncomplicated, singleton pregnancy and intact membranes in preterm labor between 24\^0/7 and 33\^6/7 weeks of gestation. Eligible maternal subjects will be randomly assigned in a 1:1 ratio to receive either retosiban IV infusion or placebo IV infusion over 48 hours. If not previously administered, antenatal corticosteroid treatment should be administered as either (1) two 12-mg doses of betamethasone given intramuscularly 24 hours apart or (2) four 6-mg doses of betamethasone administered intramuscularly every 12 hours. A single rescue course of antenatal corticosteroids is permitted if the antecedent treatment was at least 7 days prior to study enrolment. Investigators have discretion to use a standardized regimen of magnesium sulphate, as well as intrapartum antibiotic prophylaxis for perinatal group B streptococcal infection. Prior to randomization, each subject will be stratified by progesterone treatment and gestational age. The progesterone strata will consist of subjects on established progesterone therapy or subjects not on established progesterone therapy at Screening. The study will comprise 6 phases: Screening, Inpatient Randomized Treatment, Post Infusion Assessment, Delivery, Maternal Post-Delivery Assessment, and Neonatal Medical Review. The duration of any subject's (maternal or neonatal) participation in the study will be variable and dependent on gestational ages (GA) at study entry and the date of delivery.
Interventions
DRUGRetosiban IV infusion
Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
Sponsors
PPD Development, LP
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
12 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Signed and dated written informed consent is required prior to a subject's participation in the study and the performance of any protocol specific procedures. Adolescents aged 12 to 17 years must provide written agreement to participate in the study in accordance with applicable regulatory and country or state requirements. Subjects will also be asked to sign a release for medical records at the time of consenting to allow access to both the maternal and neonatal records including information about delivery and infant care as well as information collected prior to the consent having been signed. * Females aged 12 to 45 years, with an uncomplicated, singleton pregnancy and intact membranes in preterm. * Gestational age between 24 and 33 weeks as determined by (1) known fertilization date, either in vitro fertilization or intrauterine insemination, (2) last menstrual period confirmed by the earliest ultrasound prior to 24 weeks gestation, or (3) the earliest ultrasound alone prior to 24 weeks gestation, whichever is the most accurate method available for each subject. In situations where prenatal ultrasound records are not available at the time the subject presents, the investigator will make every effort to obtain these records (either via computer records, directly from the subject's primary care obstetrician, or via telephone). However, in cases in which these records are not readily available (e.g., off hours, holiday), it is within the investigator's discretion to use GA based on a verbal history from the subject with the intent of getting confirmation from the medical records as soon as possible. * Females must be diagnosed with preterm labor according to both of the following criteria: a) Regular uterine contractions at a rate of \>=4 contractions of at least 30 seconds' duration during a 30-minute interval confirmed by tocodynamometry and at least 1 of the following, b) Cervical dilation \>=2 centimeter (cm) and \<=4 cm by digital cervical examination or c) If \<2 cm dilation by digital cervical examination, a cervical change consisting of an increase of at least 25% effacement or 1-cm dilation. * Current or past tocolytic treatment as follows: a) Subjects in whom tocolytic treatment has not been initiated prior to consent are eligible for the study, b) Transferred or referred subjects for whom parenteral magnesium sulfate treatment has been started before Screening are eligible provided they meet all eligibility criteria, c) Subjects receiving a prohibited tocolytic in this study are eligible only if the treatment is stopped before randomization and provided they meet all eligibility criteria, d) Subjects with a historical failure of a tocolytic treatment in a previous episode of preterm labor during the current pregnancy are eligible provided they meet all eligibility criteria.
Exclusion criteria
* Fever with a temperature \>100.4 degree Fahrenheit (38 degree centigrade) for more than 1 hour or \>=101 degree Fahrenheit (38.3 degree centigrade) in the 24 hours prior to the start of study treatment. * Women with maternal-fetal conditions that potentially necessitate the need for delivery, such as pre-eclampsia or fetal compromise. * A fetus with any diagnosis, condition, treatment, or other factor that in the opinion of the investigator has the potential to affect or confound assessments of efficacy or safety (for example: nonreassuring fetal status, intrauterine growth restriction, major congenital anomaly). * Preterm premature rupture of membranes. * Women with any confirmed or suspected contraindication to prolongation of pregnancy, such as placental abruption, chorioamnionitis, or placenta previa. * Evidence of polyhydramnios (AFI \>25 cm) or oligohydramnios (AFI \<5 cm). * Women with co-morbid medical or obstetric conditions that in the opinion of the investigator have the potential to complicate the pregnancy course and outcomes, such as uncontrolled hypertension or uncontrolled diabetes (if known, history of glycosylated hemoglobin \>8% at any time during pregnancy), or compromise the safety of the subject, such as underlying cardiovascular disorder (specifically ischemic cardiac disease, congenital heart disease, pulmonary hypertension, valvular heart disease, arrhythmias, and cardiomyopathy). * Women with a history of substance abuse during the pregnancy or urine drug screen positive for cocaine, phencyclidine (PCP), methamphetamine, or amphetamine. * Women in whom the combination of history and screening test results is suggestive of abuse or dependency that may have the potential to complicate the pregnancy outcome. * Women with any diagnosis, condition, treatment, or other factor that, in the opinion of the investigator, has the potential to affect or confound assessments of efficacy or safety. * Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment). * History of sensitivity to any of the investigational products (IPs) or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline/ Pharmaceutical Product Development (GSK/PPD) medical monitor, contraindicates the subject's participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Delivery or Treatment Failure, Whichever Occurs First | Up to 17 weeks | Time to delivery or treatment failure is the number of days from the first dose of study treatment until delivery or treatment failure whichever occurs first. Treatment failure is defined as the administration of any putative tocolytic medication for treatment of preterm labor or as prophylaxis of preterm labor. Maternal intent-to-treat (ITT) Population comprised of all mothers randomly assigned to treatment who have been exposed to study treatment irrespective of their compliance to the planned course of treatment. The mean number of days to delivery or treatment failure along with standard deviation has been presented. Statistical analysis was not performed due to early termination of the study and resultant small sample size. |
| Number of Neonates With Any Diagnosis From the Neonatal Morbidity and Mortality Composite Component | Up to 28 days after the estimated date of delivery (EDD) of 40 0/7 weeks | The neonatal composite endpoint was determined from review of medical records and included the following components: fetal or neonatal death, respiratory distress syndrome (RDS), bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis based on positive blood culture with clinical features of sepsis, meningitis based on positive results for cerebrospinal fluid culture performed as part of infection workup, retinopathy of prematurity, intraventricular hemorrhage (IVH), white matter injury and cerebellar hemorrhage. Neonates with any of the composite component has been presented. Statistical analysis was not performed due to early termination of study and resultant small sample size. Neonatal ITT Population comprised of all neonates whose mothers were the randomized participants who have been exposed to study treatment, that is, mothers from the ITT Population. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Births at Term | Up to 17 weeks | Participants were considered to have delivered at term if the gestational age was \>=37 0/7. The number of participants who delivered at term, that is, 37 0/7 to 41 6/7 weeks gestation has been presented. |
| Length of Neonatal Hospital Stay | Up to 28 days post EDD of 40 0/7 weeks gestation | The length of stay was collected from medical records and was calculated as the days between the delivery date and time and discharge date and time. |
| Number of Participants With Births Prior to 35 0/7 Weeks Gestation | Up to 11 weeks | The number of participants who delivered prior to 35 0/7 weeks gestation has been presented. |
| Number of Participants With Births Prior to 32 0/7 Weeks Gestation | Up to 8 weeks | The number of participants who delivered prior to 32 0/7 weeks gestation has been presented. Only those maternal participants who were randomized prior to 32 0/7 week's gestation and delivered were included. |
| Number of Participants With Births Prior to 28 0/7 Weeks Gestation | Up to 4 weeks | The number of participants who delivered prior to 28 0/7 weeks gestation has been presented. Only those maternal participants who were randomized prior to 28 0/7 week's gestation and delivered were included. |
| Number of Participants With Births <=7 Days From the First Study Treatment | Up to 7 days | The number of participants who delivered in less than or equal to 7 days from first dose of study treatment has been presented. |
| Number of Participants With Births at <=48 Hours From the First Study Treatment | Up to 48 hours | The number of participants who delivered in less than or equal to 48 hours from first dose of study treatment has been presented. |
| Number of Participants With Births at <=24 Hours From the First Study Treatment | Up to 24 hours | The number of participants who delivered in less than or equal to 24 hours from first dose of study treatment has been presented. |
| Number of Neonates With Any of the Co-primary Composite Neonatal Morbidity and Mortality, Excluding RDS | Up to 28 weeks after EDD (40 weeks gestation) | The neonatal composite endpoint was determined from review of medical records and included the following components: fetal or neonatal death, RDS, bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis based on positive blood culture with clinical features of sepsis, meningitis based on positive results for cerebrospinal fluid culture performed as part of infection workup, retinopathy of prematurity, IVH, white matter injury and cerebellar hemorrhage. The number of neonates with any co-primary composite neonatal morbidity and mortality component, excluding RDS has been presented. |
| Retosiban Clearance | Day 1 (2 to 4 hours, 10 to 14 hours) and Day 2 (22 to 26 hours, and 48 to 54 hours) post-infusion | Maternal blood samples were collected at the indicated time points for pharmacokinetic analysis. Data is a combined data set. Data is presented for 10 participants from retosiban arm of study 200719 (NCT02377466) and 43 participants from retosiban arm of study 200721 (NCT02292771). |
| Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Up to 28 days after the EDD of 40 0/7 weeks | The neonatal composite endpoint was determined from review of medical records and included the following components: fetal or neonatal death, RDS, bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis based on positive blood culture with clinical features of sepsis, meningitis based on positive results for cerebrospinal fluid culture performed as part of infection workup, retinopathy of prematurity, IVH, white matter injury and cerebellar hemorrhage. The number of neonates with each individual component of the composite component has been presented. |
| Number of Neonatal Participants With Admission to a Particular Hospital Unit | Up to 28 days post EDD (40 0/7 weeks gestation) | Neonatal healthcare resource utilization was collected from review of medical records. The number of neonatal participants who were admitted to a particular hospital unit that is, level III (or higher) intensive neonatal care (NICU), Intensive care unit (ICU), general ward, Level I - Basic Neonatal care, Well born nursery (SCBU) and Level II-Special Care Newborn nursery high dependency (NHDU) has been summarized. Neonatal Safety Population consisted of neonates whose mothers received study treatment. |
| Length of Stay in Specialized Care Unit | Up to 28 days post EDD (40 0/7 weeks gestation) | Neonatal healthcare resource utilization was collected from review of medical records. The length of stay in a specialized care unit (NICU or ICU) has been presented for neonatal participants with admission to ICU or NICU. |
| Number of Newborn Participants With Hospital Readmission | Up to 28 days of EDD (40 0/7 weeks gestation) | Newborn hospital readmission following hospitalization for birth was collected from the newborn's medical records. The number of newborn participants who had readmission to hospital is presented. |
| Length of Stay Following Readmission to Hospital | Up to 28 days after EDD (40 0/7 weeks gestation) | Newborn hospital readmission following hospitalization for birth was collected from the newborn's medical records. Length of stay in hospital following readmission is presented for neonates. |
| Number of Participants With Ambulatory Surgery | Up to 28 days post EDD (40 0/7 weeks gestation) | Information regarding participants who had ambulatory surgery was collected from the newborn medical records. The number of neonatal participants with ambulatory surgery is presented. |
| Time to Treatment Failure | Up to 17 weeks | Treatment failure is defined as the administration of any putative tocolytic medication for treatment of preterm labor or as prophylaxis of preterm labor. Time to treatment failure is the number of days from the first dose of study treatment until treatment failure. The mean number of days to delivery or treatment failure along with standard deviation has been presented. Only those maternal participants with treatment failure were included in the analysis. NA indicates standard deviation could not be calculated as only one participant was analyzed. |
| Number of Participants Who Received Any Putative Tocolytic | Up to 17 weeks | A putative tocolytic medication was the medication administered for active preterm labor or as prevention of preterm labor and included calcium channel blockers, nonsteroidal anti-inflammatory drugs, or beta agonists, or magnesium sulfate doses that exceeded prespecified IV loading doses, infusion rates, or total duration of administration. |
| Number of Participants With Subsequent Preterm Labor | Up to 11 weeks | The participants who had not delivered after 48 hours post-infusion were contacted to determine if they had delivered or experienced any subsequent episodes of preterm labor. A subsequent episode of preterm labor was only recorded if the participant reported it to the Principal Investigator during one of the telephone follow-up calls but did not then go on to immediately deliver. However, if labor started and led to immediate delivery, then the only data collected would be the pre-specified delivery data and thus would not be counted as a subsequent episode of preterm labor. The number of participants who had a subsequent episode of preterm labor after administration of the study treatment has been presented. Maternal Safety Population comprised of all maternal participants randomly assigned to treatment who have been exposed to study treatment. |
| Number of Maternal Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 6 weeks after delivery | An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that mey require medical or surgical intervention to prevent one of the other outcomes described before; is associated with liver injury and impaired liver function. Maternal Safety Population comprised of all mothers randomly assigned to treatment who have been exposed to study treatment. The number of maternal participants who experienced at least one AE and one SAE has been presented. |
| Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | Baseline and up to 9 days | SBP and DBP were measured with participants in a semirecumbent or seated position. SBP and DBP were measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Heart Rate | Baseline and up to 9 days | Heart rate was measured with the participants in a semirecumbent or seated position. Heart rate was measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Temperature | Baseline and up to 1 week | Temperature was measured with the participants in a semirecumbent or seated position. Temperature was measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Respiratory Rate | Baseline and up to 1 week | Respiratory rate was measured with the participants in a semirecumbent or seated position. Respiratory rate was measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Hematocrit Levels | Baseline and up to 1 week | Blood samples were collected for the evaluation of change in hematocrit levels from Baseline. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | Baseline and up to 1 week | Blood samples were collected for the evaluation of change in hemoglobin levels and MCHC from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Baseline and up to 1 week | Blood samples were collected for the evaluation of change in basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes count. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | Baseline and up to 1 week | Blood samples were collected for the evaluation of change in MCV and MPV from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Erythrocyte Level | Baseline and up to 1 week | Blood samples were collected for the evaluation of change in erythrocyte level from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | Baseline and up to 1 week | Blood samples were collected for the evaluation of change in ALP, ALT, AST, GGT and LDH from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Albumin and Protein Levels | Baseline and up to 1 week | Blood samples were collected for the evaluation of change in albumin and protein levels from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Baseline and up to 1 week | Blood samples were collected for the evaluation of change from Baseline in levels of anion gap, calcium, chloride, carbon dioxide, glucose, potassium, magnesium, phosphate, and sodium. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Baseline and up to 1 week | Blood samples were collected for the evaluation of change from Baseline in levels of direct bilirubin, bilirubin, indirect bilirubin, creatinine and urate. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). |
| Number of Participants Who Discontinued Study Treatment Due to Clinical and Laboratory Toxicities | Up to 48 hours post-infusion | Number of maternal participants who discontinued study treatment due to clinical and laboratory toxicities is presented. |
| Number of Maternal Participants With a Score of 12 or Higher on the Edinburgh Postnatal Depression Scale (EPDS) | Up to 6 weeks post delivery | The effect of preterm birth on maternal health status was assessed using the EPDS. The EPDS is a 10-item self-reported assessment of depression, validated for administration during both the antenatal and the post-natal periods. Items are rated on a 4-point variable Likert scale, ranging from 0 to 3. The total score was calculated by adding individual scores for each item and ranged from 0 to 30. A score of less than 8 indicates depression not likely; score of 9 to 11 indicates possible depression and a score of more than 12 indicates an increased probability of depression. Maternal participants were required to complete the EPDS at the maternal follow-up assessment 6 weeks post-delivery. |
| Number of Maternal Participants With AEs of Special Interest (AESI). | Up to 6 weeks post-delivery | Maternal AESI included: maternal death; chorioamnionitis and its complications (clinical chorioamnionitis, preterm premature rupture of membranes, endomyometritis, wound infection, pelvic abscess, bacteremia, septic shock, disseminated intravascular coagulation, and adult RDS); placental abruption; postpartum hemorrhage - postpartum hemorrhage and/or retained placenta and pulmonary edema. The number of participants with at least one AESI has been presented. |
| Number of Maternal Participants With Disease Related AEs (DRE) | Up to 6 weeks post-delivery | Maternal DREs included: signs and symptoms of labor discomfort (example, cramping, backache, muscle aches, nausea); subsequent episodes of preterm labor and hospitalization for delivery. The number of participants with at least one DRE has been presented. |
| Number of Fetal Participants With AEs and SAEs Prior to Delivery | Up to 17 weeks post-infusion | An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the other outcomes described before; is associated with liver injury and impaired liver function. Fetal AEs and SAEs included the adverse events that were experienced by the fetus prior to delivery. The number of fetal participants who experienced at least one AE and one SAE has been presented. |
| Number of Participants With Fetal Acidosis | Up to 16 weeks | The number of participants with fetal acidosis is presented. |
| Number of Participants With Different Modes of Transportation to Hospital | Up to 28 days post EDD (40 0/7 weeks gestation) | The means by which the maternal participants were transported to the hospital i.e. ground ambulance/emergency vehicle (gr. amb/emer. veh), air ambulance, family member or other means were obtained from the review of medical records. The number of maternal participants with the corresponding mode of transportation is presented for preterm labor visit and delivery visit. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles). |
| Number of Participants With Fetal AESI | Up to 17 weeks | Fetal AESI included: intrauterine fetal demise; category II or III fetal heart rate tracing; and fetal inflammatory response syndrome characterized by cord blood interleukin-6 \>11 picogram per milliliter (pg/mL), funisitis, or chorionic vasculitis. The number of participants who experienced at least one AESI has been presented. |
| Neonatal APGAR Scores | Up to 5 minutes after birth | APGAR is a quick test to assess the health of new born children. The test is performed at 1 and 5 minutes after birth. APGAR scale is determined by evaluating the new born on five categories (appearance, pulse, grimace, activity and respiration) on a scale from zero to two, then summing up the five values obtained. APGAR score ranges from 0 to 10 where a score of 7 and above is normal. The mean and standard deviation of APGAR scores at one minute and at five minutes of birth has been presented. |
| Weight of Neonates | Up to 17 weeks | The weight of neonates was obtained from the neonate birth record. The mean weight of neonates and standard deviation has been presented. |
| Head Circumference of Neonates | Up to 17 weeks | The head circumference was determined from the neonate birth record. |
| Number of Neonatal Participants With AEs and SAEs | Up to 28 days after the EDD of 40 weeks gestation | An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the other outcomes described before; is associated with liver injury and impaired liver function. The number of participants who experienced at least one AE and one SAE has been presented. Neonatal Safety Population consisted of neonates whose mothers received randomized treatment. |
| Number of Neonatal Participants With AESI | Up to 28 days after EDD of 40 weeks gestation | Neonatal AESI included: Neonatal death; Asphyxia; Infections (early onset neonatal sepsis, septic shock, pneumonia, meningitis); RDS; Hypotension; IVH/periventricular leukomalacia; Bronchopulmonary dysplasia; Neonatal acidosis; Hyperbilirubinemia; Necrotizing enterocolitis; and Hypoxic ischemic encephalopathy. The number of neonatal participants who experienced at least one AESI has been presented. |
| Time to Delivery | Up to 17 weeks | The time to delivery was calculated as the days between the delivery and start time of the study treatment infusion using the formula: Time to delivery (days) = (date and time of delivery minus date and time of start of infusion) divided by (24 multiplied by 60). The mean number of days to delivery along with standard deviation has been presented. |
| Maternal Length of Stay in Hospital | Up to 28 days post EDD (40 0/7 weeks gestation) | Details on maternal health care resource use (both for hospitalizations related to preterm labor not resulting in a delivery and hospitalizations related to preterm labor/normal labor resulting in a delivery) associated with an episode of preterm labor, preterm delivery and normal term delivery (\>= 37 weeks gestation) were collected from review of medical records. Length of hospital stay associated with hospital admission for preterm labor and normal term labor/term delivery is presented. One participant in the retosiban arm did not have hospitalization data; hence, was excluded from the analysis at delivery. Only participants with data available at the specified time points were analyzed (indicated by n=X) in category titles. NA indicates standard deviation could not be calculated as only one participant was analyzed. |
| Number of Participants With Hospital Admissions Related to Preterm Labor and Preterm Delivery | Up to 28 days after EDD (40 0/7 weeks of gestation) | Maternal healthcare resource utilization associated with an episode of preterm labor and preterm delivery were collected from the review of medical records. One participant in the retosiban arm did not have hospitalization data; hence, was excluded from the analysis at delivery. The number of participants who had hospital admission for preterm labor and preterm delivery has been presented. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). |
| Number of Participants Admitted to Particular Hospital Unit | Up to 28 days post EDD (40 0/7 weeks gestation) | Maternal healthcare resource utilization associated with an episode of preterm labor, preterm delivery and normal term delivery were collected from the review of medical records. The number of participants who were admitted to a particular hospital unit has been presented. |
| Volume of Distribution of Retosiban | Day 1 (2 to 4 hours, 10 to 14 hours) and Day 2 (22 to 26 hours, and 48 to 54 hours) post-infusion | Maternal blood samples were collected at the indicated time points for pharmacokinetic analysis. Data is a combined data set. Data is presented for 10 participants from retosiban arm of study 200719 (NCT02377466) and 43 participants from retosiban arm of study 200721 (NCT02292771). |
| Number of Neonatal Participants With DRE | Up to 28 days after EDD of 40 weeks gestation | The disease related neonatal events occurring in Infants born prior to 37 completed weeks included: apnea (severe), respiratory failure due to fatigue, hypoxia, or air leak from alveolar injury, patent ductus arteriosus, bradycardia, ventriculomegaly, cerebellar hemorrhage, hydrocephalus other than congenital, gastroesophageal reflux, aspiration pneumonia, anemia, retinopathy of prematurity (all stages), hearing disorder, temperature instability and hypoglycemia. The number of participants with at least one DRE has been presented. |
| Number of Participants With Births Prior to 37 0/7 Weeks Gestation | Up to 13 weeks | Gestational age at birth (weeks) is defined as the gestational age when the baby is born. Participants were considered to have delivered prior to 37 0/7 weeks, that is preterm, if the gestational age at birth is less than 37 0/7 weeks. The number of participants who delivered prior to 37 0/7 weeks gestation has been presented. |
Countries
Canada, Italy, Japan, United Kingdom, United States
Participant flow
Recruitment details
NEWBORN-1 was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to investigate efficacy and safety of retosiban in female participants aged 12 to 45 years with an uncomplicated singleton pregnancy in preterm labor with intact membranes between 24 0/7 and 33 6/7 weeks gestation. The study was conducted in 3 countries.
Pre-assignment details
Twenty-five participants were randomly assigned to study treatments: 12 participants to retosiban intravenous (IV) infusion and 13 participants to matched placebo IV infusion. Two participants randomized to retosiban arm did not receive study treatment. The study was terminated early due to feasibility of recruiting the study in a timely manner.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Placebo was 0.9 percent sodium chloride infusion matched for retosiban volume, IV loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment. | 13 |
| Retosiban Participants were administered 6 milligram (mg) IV loading dose of retosiban over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg/hour continuous infusion for remainder of 48-hour treatment period. | 10 |
| Total | 23 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Other: Randomized and not treated | 0 | 2 |
Baseline characteristics
| Characteristic | Retosiban | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 27.7 Years STANDARD_DEVIATION 6.73 | 27.0 Years STANDARD_DEVIATION 6.63 | 26.5 Years STANDARD_DEVIATION 6.78 |
| Race/Ethnicity, Customized African American/African Heritage | 2 Participants | 4 Participants | 2 Participants |
| Race/Ethnicity, Customized Asian-Central/South Asian Heritage | 1 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian-East Asian Heritage | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian-Japanese Heritage | 2 Participants | 6 Participants | 4 Participants |
| Race/Ethnicity, Customized Asian-South East Asian Heritage | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized White-White/Caucasian/European Heritage | 5 Participants | 10 Participants | 5 Participants |
| Sex: Female, Male Female | 10 Participants | 23 Participants | 13 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 13 | 0 / 10 | 0 / 13 | 0 / 10 | 0 / 13 | 0 / 10 |
| other Total, other adverse events | 6 / 13 | 6 / 10 | 3 / 13 | 5 / 10 | 8 / 13 | 7 / 10 |
| serious Total, serious adverse events | 0 / 13 | 0 / 10 | 0 / 13 | 1 / 10 | 3 / 13 | 5 / 10 |
Outcome results
Primary
Number of Neonates With Any Diagnosis From the Neonatal Morbidity and Mortality Composite Component
The neonatal composite endpoint was determined from review of medical records and included the following components: fetal or neonatal death, respiratory distress syndrome (RDS), bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis based on positive blood culture with clinical features of sepsis, meningitis based on positive results for cerebrospinal fluid culture performed as part of infection workup, retinopathy of prematurity, intraventricular hemorrhage (IVH), white matter injury and cerebellar hemorrhage. Neonates with any of the composite component has been presented. Statistical analysis was not performed due to early termination of study and resultant small sample size. Neonatal ITT Population comprised of all neonates whose mothers were the randomized participants who have been exposed to study treatment, that is, mothers from the ITT Population.
Time frame: Up to 28 days after the estimated date of delivery (EDD) of 40 0/7 weeks
Population: Neonatal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Neonates With Any Diagnosis From the Neonatal Morbidity and Mortality Composite Component | 4 Participants |
| Retosiban | Number of Neonates With Any Diagnosis From the Neonatal Morbidity and Mortality Composite Component | 2 Participants |
Primary
Time to Delivery or Treatment Failure, Whichever Occurs First
Time to delivery or treatment failure is the number of days from the first dose of study treatment until delivery or treatment failure whichever occurs first. Treatment failure is defined as the administration of any putative tocolytic medication for treatment of preterm labor or as prophylaxis of preterm labor. Maternal intent-to-treat (ITT) Population comprised of all mothers randomly assigned to treatment who have been exposed to study treatment irrespective of their compliance to the planned course of treatment. The mean number of days to delivery or treatment failure along with standard deviation has been presented. Statistical analysis was not performed due to early termination of the study and resultant small sample size.
Time frame: Up to 17 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Time to Delivery or Treatment Failure, Whichever Occurs First | 11.10 Days | Standard Deviation 14.987 |
| Retosiban | Time to Delivery or Treatment Failure, Whichever Occurs First | 18.91 Days | Standard Deviation 22.993 |
Secondary
Change From Baseline in Albumin and Protein Levels
Blood samples were collected for the evaluation of change in albumin and protein levels from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Albumin and Protein Levels | Albumin; Day 2; n=9, 5 | -3.4 grams per liter (g/L) | Standard Deviation 3.68 |
| Placebo | Change From Baseline in Albumin and Protein Levels | Albumin; post-infusion assessment; n=7, 5 | -1.3 grams per liter (g/L) | Standard Deviation 2.21 |
| Placebo | Change From Baseline in Albumin and Protein Levels | Protein; Day 2; n=9, 5 | -5.8 grams per liter (g/L) | Standard Deviation 6.26 |
| Placebo | Change From Baseline in Albumin and Protein Levels | Protein; post-infusion assessment; n=7, 5 | -2.4 grams per liter (g/L) | Standard Deviation 3.41 |
| Retosiban | Change From Baseline in Albumin and Protein Levels | Protein; post-infusion assessment; n=7, 5 | -1.8 grams per liter (g/L) | Standard Deviation 5.02 |
| Retosiban | Change From Baseline in Albumin and Protein Levels | Albumin; Day 2; n=9, 5 | -2.6 grams per liter (g/L) | Standard Deviation 1.67 |
| Retosiban | Change From Baseline in Albumin and Protein Levels | Protein; Day 2; n=9, 5 | -5.4 grams per liter (g/L) | Standard Deviation 3.58 |
| Retosiban | Change From Baseline in Albumin and Protein Levels | Albumin; post-infusion assessment; n=7, 5 | -1.0 grams per liter (g/L) | Standard Deviation 2.35 |
Secondary
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels
Blood samples were collected for the evaluation of change in ALP, ALT, AST, GGT and LDH from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALP; Day 2; n=9, 5 | -17.3 International Units per liter (IU/L) | Standard Deviation 17.56 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALP; post-infusion assessment; n=8, 6 | 6.6 International Units per liter (IU/L) | Standard Deviation 31.14 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALT; Day 2; n=9, 5 | 3.9 International Units per liter (IU/L) | Standard Deviation 19.6 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALT; post-infusion assessment; n=8, 6 | -8.8 International Units per liter (IU/L) | Standard Deviation 20.04 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | AST; Day 2; n=9, 5 | 4.4 International Units per liter (IU/L) | Standard Deviation 15.69 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | AST; post-infusion assessment; n=8, 6 | -9.1 International Units per liter (IU/L) | Standard Deviation 13.05 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | GGT; Day 2; n=9, 5 | -0.9 International Units per liter (IU/L) | Standard Deviation 1.69 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | GGT; post-infusion assessment; n=7, 5 | 4.4 International Units per liter (IU/L) | Standard Deviation 2.57 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | LDH; Day 2; n=9, 5 | -6.7 International Units per liter (IU/L) | Standard Deviation 33.51 |
| Placebo | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | LDH; post-infusion assessment; n=7, 5 | -8.1 International Units per liter (IU/L) | Standard Deviation 21.93 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | GGT; post-infusion assessment; n=7, 5 | 0.4 International Units per liter (IU/L) | Standard Deviation 2.07 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALP; Day 2; n=9, 5 | -11.8 International Units per liter (IU/L) | Standard Deviation 6.46 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | AST; post-infusion assessment; n=8, 6 | -0.5 International Units per liter (IU/L) | Standard Deviation 7.45 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALP; post-infusion assessment; n=8, 6 | -2.8 International Units per liter (IU/L) | Standard Deviation 14.08 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | LDH; post-infusion assessment; n=7, 5 | -7.6 International Units per liter (IU/L) | Standard Deviation 31.76 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALT; Day 2; n=9, 5 | 4.4 International Units per liter (IU/L) | Standard Deviation 10.64 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | GGT; Day 2; n=9, 5 | -0.8 International Units per liter (IU/L) | Standard Deviation 1.3 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | ALT; post-infusion assessment; n=8, 6 | 2.5 International Units per liter (IU/L) | Standard Deviation 5.5 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | LDH; Day 2; n=9, 5 | -26.4 International Units per liter (IU/L) | Standard Deviation 31.86 |
| Retosiban | Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels | AST; Day 2; n=9, 5 | 2.0 International Units per liter (IU/L) | Standard Deviation 10.2 |
Secondary
Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level
Blood samples were collected for the evaluation of change from Baseline in levels of anion gap, calcium, chloride, carbon dioxide, glucose, potassium, magnesium, phosphate, and sodium. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Anion Gap; Day 2; n=8, 4 | 0.0 millimoles per liter (mmol/L) | Standard Deviation 4.72 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Anion Gap; post-infusion assessment; n=7, 4 | -1.6 millimoles per liter (mmol/L) | Standard Deviation 5.26 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Calcium; Day 2; n=9, 5 | -0.042 millimoles per liter (mmol/L) | Standard Deviation 0.2833 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Calcium; post-infusion assessment; n=7, 5 | 0.091 millimoles per liter (mmol/L) | Standard Deviation 0.2052 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Chloride; Day 2; n=9, 5 | 1.0 millimoles per liter (mmol/L) | Standard Deviation 5.17 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Chloride; post-infusion assessment; n=7, 5 | -0.7 millimoles per liter (mmol/L) | Standard Deviation 3.35 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Carbon Dioxide; Day 2; n=9, 5 | -0.2 millimoles per liter (mmol/L) | Standard Deviation 3.63 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Carbon Dioxide; post-infusion assessment; n=7, 5 | 2.3 millimoles per liter (mmol/L) | Standard Deviation 3.64 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Glucose; Day 2; n=9, 5 | 1.47 millimoles per liter (mmol/L) | Standard Deviation 1.639 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Glucose; post-infusion assessment; n=7, 5 | 0.11 millimoles per liter (mmol/L) | Standard Deviation 2.497 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Potassium; Day 2; n=9, 5 | -0.16 millimoles per liter (mmol/L) | Standard Deviation 0.394 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Potassium; post-infusion assessment; n=7, 5 | -0.16 millimoles per liter (mmol/L) | Standard Deviation 0.237 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Magnesium; Day 2; n=9, 5 | -0.411 millimoles per liter (mmol/L) | Standard Deviation 0.9476 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Magnesium; post-infusion assessment; n=7, 5 | -0.449 millimoles per liter (mmol/L) | Standard Deviation 0.6473 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Phosphate; Day 2; n=9, 5 | -0.133 millimoles per liter (mmol/L) | Standard Deviation 0.1768 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Phosphate; post-infusion assessment; n=7, 5 | 0.021 millimoles per liter (mmol/L) | Standard Deviation 0.2018 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Sodium; Day 2; n=9, 5 | 1.4 millimoles per liter (mmol/L) | Standard Deviation 2.96 |
| Placebo | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Sodium; post-infusion assessment; n=7, 5 | 0.1 millimoles per liter (mmol/L) | Standard Deviation 2.12 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Magnesium; post-infusion assessment; n=7, 5 | -0.056 millimoles per liter (mmol/L) | Standard Deviation 0.6199 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Anion Gap; Day 2; n=8, 4 | 0.0 millimoles per liter (mmol/L) | Standard Deviation 1.83 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Glucose; post-infusion assessment; n=7, 5 | 0.28 millimoles per liter (mmol/L) | Standard Deviation 2.109 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Anion Gap; post-infusion assessment; n=7, 4 | 0.3 millimoles per liter (mmol/L) | Standard Deviation 2.22 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Sodium; post-infusion assessment; n=7, 5 | -0.8 millimoles per liter (mmol/L) | Standard Deviation 1.64 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Calcium; Day 2; n=9, 5 | -0.040 millimoles per liter (mmol/L) | Standard Deviation 0.1208 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Potassium; Day 2; n=9, 5 | 0.10 millimoles per liter (mmol/L) | Standard Deviation 0.515 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Calcium; post-infusion assessment; n=7, 5 | -0.048 millimoles per liter (mmol/L) | Standard Deviation 0.1016 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Phosphate; Day 2; n=9, 5 | 0.030 millimoles per liter (mmol/L) | Standard Deviation 0.2928 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Chloride; Day 2; n=9, 5 | 1.8 millimoles per liter (mmol/L) | Standard Deviation 2.17 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Potassium; post-infusion assessment; n=7, 5 | 0.10 millimoles per liter (mmol/L) | Standard Deviation 0.283 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Chloride; post-infusion assessment; n=7, 5 | -0.6 millimoles per liter (mmol/L) | Standard Deviation 2.3 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Sodium; Day 2; n=9, 5 | 0.4 millimoles per liter (mmol/L) | Standard Deviation 1.67 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Carbon Dioxide; Day 2; n=9, 5 | 0.0 millimoles per liter (mmol/L) | Standard Deviation 2.35 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Magnesium; Day 2; n=9, 5 | -0.236 millimoles per liter (mmol/L) | Standard Deviation 0.5428 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Carbon Dioxide; post-infusion assessment; n=7, 5 | -0.2 millimoles per liter (mmol/L) | Standard Deviation 2.77 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Phosphate; post-infusion assessment; n=7, 5 | 0.110 millimoles per liter (mmol/L) | Standard Deviation 0.1557 |
| Retosiban | Change From Baseline in Anion Gap, Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level | Glucose; Day 2; n=9, 5 | 1.98 millimoles per liter (mmol/L) | Standard Deviation 1.064 |
Secondary
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count
Blood samples were collected for the evaluation of change in basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes count. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Basophils; Day 2; n=9, 3 | -0.003 Billion cells per liter (L) | Standard Deviation 0.0132 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Basophils; post-infusion assessment; n=7, 5 | 0.003 Billion cells per liter (L) | Standard Deviation 0.016 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Eosinophils; Day 2; n=9, 3 | 0.004 Billion cells per liter (L) | Standard Deviation 0.0938 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Eosinophils; post-infusion assessment; 7, 5 | 0.064 Billion cells per liter (L) | Standard Deviation 0.1321 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Lymphocytes; Day 2; n=9, 3 | 0.323 Billion cells per liter (L) | Standard Deviation 0.6117 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Lymphocytes; post-infusion assessment; 7, 5 | 0.253 Billion cells per liter (L) | Standard Deviation 1.0579 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Monocytes; Day 2; n=9, 3 | 0.008 Billion cells per liter (L) | Standard Deviation 0.3389 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Monocytes; post-infusion assessment; 7, 5 | 0.141 Billion cells per liter (L) | Standard Deviation 0.2535 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Neutrophils; Day 2; n=9, 3 | 2.744 Billion cells per liter (L) | Standard Deviation 6.9362 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Neutrophils; post-infusion assessment; 7, 5 | -2.246 Billion cells per liter (L) | Standard Deviation 6.0323 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Platelets; Day 2; n=8, 3 | -6.4 Billion cells per liter (L) | Standard Deviation 47.42 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Platelets; post-infusion assessment; 6, 5 | -15.7 Billion cells per liter (L) | Standard Deviation 60.48 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Leukocytes; Day 2; n=9, 3 | 3.10 Billion cells per liter (L) | Standard Deviation 6.72 |
| Placebo | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Leukocytes; post-infusion assessment; 7, 5 | -1.76 Billion cells per liter (L) | Standard Deviation 5.358 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Platelets; Day 2; n=8, 3 | -24.7 Billion cells per liter (L) | Standard Deviation 32.58 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Basophils; Day 2; n=9, 3 | 0.000 Billion cells per liter (L) | Standard Deviation 0.0458 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Monocytes; post-infusion assessment; 7, 5 | -0.082 Billion cells per liter (L) | Standard Deviation 0.4135 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Basophils; post-infusion assessment; n=7, 5 | 0.058 Billion cells per liter (L) | Standard Deviation 0.1103 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Leukocytes; Day 2; n=9, 3 | -0.87 Billion cells per liter (L) | Standard Deviation 2.914 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Eosinophils; Day 2; n=9, 3 | -0.063 Billion cells per liter (L) | Standard Deviation 0.0513 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Neutrophils; Day 2; n=9, 3 | -1.813 Billion cells per liter (L) | Standard Deviation 3.3001 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Eosinophils; post-infusion assessment; 7, 5 | -0.044 Billion cells per liter (L) | Standard Deviation 0.1328 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Platelets; post-infusion assessment; 6, 5 | -5.4 Billion cells per liter (L) | Standard Deviation 33.34 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Lymphocytes; Day 2; n=9, 3 | 0.877 Billion cells per liter (L) | Standard Deviation 0.1914 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Neutrophils; post-infusion assessment; 7, 5 | -1.910 Billion cells per liter (L) | Standard Deviation 2.8497 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Lymphocytes; post-infusion assessment; 7, 5 | 1.006 Billion cells per liter (L) | Standard Deviation 1.4223 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Leukocytes; post-infusion assessment; 7, 5 | -0.98 Billion cells per liter (L) | Standard Deviation 2.645 |
| Retosiban | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count | Monocytes; Day 2; n=9, 3 | 0.147 Billion cells per liter (L) | Standard Deviation 0.5773 |
Secondary
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
SBP and DBP were measured with participants in a semirecumbent or seated position. SBP and DBP were measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 9 days
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 1: 15 to 30 minutes; n=13, 10 | -3.2 millimeter of mercury (mmHg) | Standard Deviation 10.64 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 1: 4 to 8 hours; n=11, 10 | -9.0 millimeter of mercury (mmHg) | Standard Deviation 11.31 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 1: 20 to 24 hours; n=10, 8 | -13.1 millimeter of mercury (mmHg) | Standard Deviation 11.05 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 2; n=11, 7 | -10.2 millimeter of mercury (mmHg) | Standard Deviation 11.07 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Post infusion assessment; n=9, 5 | -6.6 millimeter of mercury (mmHg) | Standard Deviation 12.69 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 1: 15 to 30 minutes; n=13, 10 | -0.8 millimeter of mercury (mmHg) | Standard Deviation 7.5 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 1: 4 to 8 hours; n=11, 10 | -7.1 millimeter of mercury (mmHg) | Standard Deviation 13.09 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 1: 20 to 24 hours; n=10, 8 | -5.2 millimeter of mercury (mmHg) | Standard Deviation 12.47 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 2; n=11, 7 | -4.5 millimeter of mercury (mmHg) | Standard Deviation 11.86 |
| Placebo | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Post infusion assessment; n=9, 5 | -9.6 millimeter of mercury (mmHg) | Standard Deviation 8.69 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 1: 20 to 24 hours; n=10, 8 | 2.6 millimeter of mercury (mmHg) | Standard Deviation 14.56 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 1: 15 to 30 minutes; n=13, 10 | -6.8 millimeter of mercury (mmHg) | Standard Deviation 8.22 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 1: 15 to 30 minutes; n=13, 10 | -3.1 millimeter of mercury (mmHg) | Standard Deviation 10.4 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 1: 4 to 8 hours; n=11, 10 | -7.0 millimeter of mercury (mmHg) | Standard Deviation 10.14 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Post infusion assessment; n=9, 5 | -7.0 millimeter of mercury (mmHg) | Standard Deviation 8.22 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 1: 20 to 24 hours; n=10, 8 | -6.5 millimeter of mercury (mmHg) | Standard Deviation 8.65 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 1: 4 to 8 hours; n=11, 10 | -1.3 millimeter of mercury (mmHg) | Standard Deviation 9.06 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Day 2; n=11, 7 | -4.0 millimeter of mercury (mmHg) | Standard Deviation 6.66 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP; Day 2; n=11, 7 | 0.7 millimeter of mercury (mmHg) | Standard Deviation 10.21 |
| Retosiban | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP; Post infusion assessment; n=9, 5 | -2.8 millimeter of mercury (mmHg) | Standard Deviation 4.76 |
Secondary
Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels
Blood samples were collected for the evaluation of change from Baseline in levels of direct bilirubin, bilirubin, indirect bilirubin, creatinine and urate. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Direct Bilirubin; Day 2; n=9, 5 | 0.0 micromoles per liter (µmol/L) | Standard Deviation 1 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Direct Bilirubin; post-infusion assessment; n=7, 5 | 0.3 micromoles per liter (µmol/L) | Standard Deviation 0.76 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Bilirubin; Day 2; n=9, 5 | -0.7 micromoles per liter (µmol/L) | Standard Deviation 1.41 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Bilirubin; post-infusion assessment; n=8, 6 | -0.3 micromoles per liter (µmol/L) | Standard Deviation 1.28 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Indirect Bilirubin; Day 2; n=9, 5 | -0.7 micromoles per liter (µmol/L) | Standard Deviation 1.41 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Indirect Bilirubin; post-infusion assessment;n=7,5 | -0.6 micromoles per liter (µmol/L) | Standard Deviation 1.51 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Creatinine; Day 2; n=6, 3 | -0.33 micromoles per liter (µmol/L) | Standard Deviation 6.812 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Creatinine; post-infusion assessment; n=6, 3 | 1.92 micromoles per liter (µmol/L) | Standard Deviation 5.075 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Urate; Day 2; n=9, 5 | 1.1 micromoles per liter (µmol/L) | Standard Deviation 24.72 |
| Placebo | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Urate; post-infusion assessment; n=7, 5 | 12.9 micromoles per liter (µmol/L) | Standard Deviation 24.3 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Creatinine; post-infusion assessment; n=6, 3 | -0.33 micromoles per liter (µmol/L) | Standard Deviation 2.695 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Direct Bilirubin; Day 2; n=9, 5 | -0.4 micromoles per liter (µmol/L) | Standard Deviation 0.89 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Indirect Bilirubin; post-infusion assessment;n=7,5 | -1.6 micromoles per liter (µmol/L) | Standard Deviation 3.85 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Direct Bilirubin; post-infusion assessment; n=7, 5 | -0.4 micromoles per liter (µmol/L) | Standard Deviation 0.89 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Urate; post-infusion assessment; n=7, 5 | -2.0 micromoles per liter (µmol/L) | Standard Deviation 40.25 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Bilirubin; Day 2; n=9, 5 | -0.8 micromoles per liter (µmol/L) | Standard Deviation 1.1 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Creatinine; Day 2; n=6, 3 | 2.37 micromoles per liter (µmol/L) | Standard Deviation 1.429 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Bilirubin; post-infusion assessment; n=8, 6 | -2.0 micromoles per liter (µmol/L) | Standard Deviation 3.1 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Urate; Day 2; n=9, 5 | -22.0 micromoles per liter (µmol/L) | Standard Deviation 13.04 |
| Retosiban | Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels | Indirect Bilirubin; Day 2; n=9, 5 | -0.4 micromoles per liter (µmol/L) | Standard Deviation 1.67 |
Secondary
Change From Baseline in Erythrocyte Level
Blood samples were collected for the evaluation of change in erythrocyte level from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Erythrocyte Level | Day 2; n=9, 3 | -0.39 Trillion cells per liter | Standard Deviation 0.423 |
| Placebo | Change From Baseline in Erythrocyte Level | Post-infusion assessment; n=7, 5 | -0.03 Trillion cells per liter | Standard Deviation 0.33 |
| Retosiban | Change From Baseline in Erythrocyte Level | Day 2; n=9, 3 | -0.53 Trillion cells per liter | Standard Deviation 0.153 |
| Retosiban | Change From Baseline in Erythrocyte Level | Post-infusion assessment; n=7, 5 | -0.02 Trillion cells per liter | Standard Deviation 0.303 |
Secondary
Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV)
Blood samples were collected for the evaluation of change in MCV and MPV from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MCV; Day 2; n=9, 3 | 0.4 femtoliter (fL) | Standard Deviation 2.79 |
| Placebo | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MCV; Post-infusion assessment; n=7, 5 | -1.9 femtoliter (fL) | Standard Deviation 1.77 |
| Placebo | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MPV; Post-infusion assessment; n=6, 5 | 0.02 femtoliter (fL) | Standard Deviation 0.833 |
| Placebo | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MPV; Day 2; n=8, 3 | -0.11 femtoliter (fL) | Standard Deviation 0.455 |
| Retosiban | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MPV; Post-infusion assessment; n=6, 5 | 0.48 femtoliter (fL) | Standard Deviation 1.026 |
| Retosiban | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MCV; Day 2; n=9, 3 | 1.7 femtoliter (fL) | Standard Deviation 4.73 |
| Retosiban | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MCV; Post-infusion assessment; n=7, 5 | -0.8 femtoliter (fL) | Standard Deviation 1.3 |
| Retosiban | Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) | MPV; Day 2; n=8, 3 | -0.20 femtoliter (fL) | Standard Deviation 0.436 |
Secondary
Change From Baseline in Heart Rate
Heart rate was measured with the participants in a semirecumbent or seated position. Heart rate was measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 9 days
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Heart Rate | Day 1: 4 to 8 hours; n=11, 10 | -2.6 beats per minute | Standard Deviation 10.82 |
| Placebo | Change From Baseline in Heart Rate | Day 2; n=11, 7 | -5.6 beats per minute | Standard Deviation 15.73 |
| Placebo | Change From Baseline in Heart Rate | Day 1: 20 to 24 hours; n=9, 8 | -4.1 beats per minute | Standard Deviation 10.61 |
| Placebo | Change From Baseline in Heart Rate | Post infusion assessment; n=9, 5 | -6.1 beats per minute | Standard Deviation 17.8 |
| Placebo | Change From Baseline in Heart Rate | Day 1: 15 to 30 minutes; n=13, 10 | -5.1 beats per minute | Standard Deviation 12.37 |
| Retosiban | Change From Baseline in Heart Rate | Post infusion assessment; n=9, 5 | -3.8 beats per minute | Standard Deviation 16.24 |
| Retosiban | Change From Baseline in Heart Rate | Day 1: 15 to 30 minutes; n=13, 10 | 1.4 beats per minute | Standard Deviation 8.13 |
| Retosiban | Change From Baseline in Heart Rate | Day 1: 4 to 8 hours; n=11, 10 | -0.3 beats per minute | Standard Deviation 8.12 |
| Retosiban | Change From Baseline in Heart Rate | Day 1: 20 to 24 hours; n=9, 8 | 6.5 beats per minute | Standard Deviation 21.64 |
| Retosiban | Change From Baseline in Heart Rate | Day 2; n=11, 7 | -3.6 beats per minute | Standard Deviation 13.91 |
Secondary
Change From Baseline in Hematocrit Levels
Blood samples were collected for the evaluation of change in hematocrit levels from Baseline. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Hematocrit Levels | Day 2; n=9, 3 | -0.0343 Proportion of red blood cells in blood | Standard Deviation 0.04324 |
| Placebo | Change From Baseline in Hematocrit Levels | Post-infusion assessment; n=7, 5 | -0.0090 Proportion of red blood cells in blood | Standard Deviation 0.029 |
| Retosiban | Change From Baseline in Hematocrit Levels | Day 2; n=9, 3 | -0.0470 Proportion of red blood cells in blood | Standard Deviation 0.02773 |
| Retosiban | Change From Baseline in Hematocrit Levels | Post-infusion assessment; n=7, 5 | -0.0078 Proportion of red blood cells in blood | Standard Deviation 0.02928 |
Secondary
Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC)
Blood samples were collected for the evaluation of change in hemoglobin levels and MCHC from Baseline. Baseline is defined as the last available assessment prior to the first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | Hemoglobin; Day 2; n=9, 3 | -11.2 grams per liter (g/L) | Standard Deviation 11.2 |
| Placebo | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | Hemoglobin; Post-infusion assessment; n=7, 5 | -1.0 grams per liter (g/L) | Standard Deviation 9.76 |
| Placebo | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | MCHC; Day 2; n=9, 3 | -0.3 grams per liter (g/L) | Standard Deviation 17.27 |
| Placebo | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | MCHC; Post-infusion assessment; n=7, 5 | 5.0 grams per liter (g/L) | Standard Deviation 8.52 |
| Retosiban | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | MCHC; Post-infusion assessment; n=7, 5 | 2.6 grams per liter (g/L) | Standard Deviation 5.41 |
| Retosiban | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | Hemoglobin; Day 2; n=9, 3 | -15.7 grams per liter (g/L) | Standard Deviation 6.66 |
| Retosiban | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | MCHC; Day 2; n=9, 3 | -2.7 grams per liter (g/L) | Standard Deviation 10.97 |
| Retosiban | Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) | Hemoglobin; Post-infusion assessment; n=7, 5 | -1.6 grams per liter (g/L) | Standard Deviation 8.79 |
Secondary
Change From Baseline in Respiratory Rate
Respiratory rate was measured with the participants in a semirecumbent or seated position. Respiratory rate was measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Respiratory Rate | Day 1: 4 to 8 hours; n=8, 9 | 1.1 breaths per minute | Standard Deviation 3.83 |
| Placebo | Change From Baseline in Respiratory Rate | Day 2; n=10, 6 | 0.9 breaths per minute | Standard Deviation 4.01 |
| Placebo | Change From Baseline in Respiratory Rate | Day 1: 20 to 24 hours; n=9, 7 | 0.3 breaths per minute | Standard Deviation 2.35 |
| Placebo | Change From Baseline in Respiratory Rate | Post infusion assessment; n=8, 4 | 0.4 breaths per minute | Standard Deviation 4.27 |
| Placebo | Change From Baseline in Respiratory Rate | Day 1: 15 to 30 minutes; n=11, 8 | 0.5 breaths per minute | Standard Deviation 3.45 |
| Retosiban | Change From Baseline in Respiratory Rate | Post infusion assessment; n=8, 4 | 0.5 breaths per minute | Standard Deviation 2.52 |
| Retosiban | Change From Baseline in Respiratory Rate | Day 1: 15 to 30 minutes; n=11, 8 | -1.1 breaths per minute | Standard Deviation 2.9 |
| Retosiban | Change From Baseline in Respiratory Rate | Day 1: 4 to 8 hours; n=8, 9 | -1.1 breaths per minute | Standard Deviation 2.15 |
| Retosiban | Change From Baseline in Respiratory Rate | Day 1: 20 to 24 hours; n=9, 7 | -1.0 breaths per minute | Standard Deviation 2.77 |
| Retosiban | Change From Baseline in Respiratory Rate | Day 2; n=10, 6 | 0.0 breaths per minute | Standard Deviation 1.79 |
Secondary
Change From Baseline in Temperature
Temperature was measured with the participants in a semirecumbent or seated position. Temperature was measured during inpatient randomized treatment phase (15 to 30 minutes, 4 to 8 hours, and 20 to 24 hours after the start of the infusion, at the end of the infusion) and at the post-infusion assessment. Baseline is the last available assessment prior to first dose of study treatment. Change from Baseline is the post-dose visit value minus Baseline. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to 1 week
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Temperature | Day 1: 4 to 8 hours; n=11, 10 | 0.087 degree Celsius | Standard Deviation 0.3947 |
| Placebo | Change From Baseline in Temperature | Day 2; n=11, 7 | 0.105 degree Celsius | Standard Deviation 0.5067 |
| Placebo | Change From Baseline in Temperature | Day 1: 20 to 24 hours; n=10, 8 | 0.104 degree Celsius | Standard Deviation 0.5413 |
| Placebo | Change From Baseline in Temperature | Post-infusion assessment; n=9, 5 | -0.136 degree Celsius | Standard Deviation 0.4668 |
| Placebo | Change From Baseline in Temperature | Day 1: 15 to 30 minutes; n=12, 9 | -0.028 degree Celsius | Standard Deviation 0.4123 |
| Retosiban | Change From Baseline in Temperature | Post-infusion assessment; n=9, 5 | 0.072 degree Celsius | Standard Deviation 0.2234 |
| Retosiban | Change From Baseline in Temperature | Day 1: 15 to 30 minutes; n=12, 9 | -0.111 degree Celsius | Standard Deviation 0.19 |
| Retosiban | Change From Baseline in Temperature | Day 1: 4 to 8 hours; n=11, 10 | -0.144 degree Celsius | Standard Deviation 0.3594 |
| Retosiban | Change From Baseline in Temperature | Day 1: 20 to 24 hours; n=10, 8 | -0.043 degree Celsius | Standard Deviation 0.3174 |
| Retosiban | Change From Baseline in Temperature | Day 2; n=11, 7 | 0.051 degree Celsius | Standard Deviation 0.2062 |
Secondary
Head Circumference of Neonates
The head circumference was determined from the neonate birth record.
Time frame: Up to 17 weeks
Population: Neonatal ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Head Circumference of Neonates | 29.57 centimeters (cm) | Standard Deviation 2.791 |
| Retosiban | Head Circumference of Neonates | 30.13 centimeters (cm) | Standard Deviation 3.059 |
Secondary
Length of Neonatal Hospital Stay
The length of stay was collected from medical records and was calculated as the days between the delivery date and time and discharge date and time.
Time frame: Up to 28 days post EDD of 40 0/7 weeks gestation
Population: Neonatal ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Length of Neonatal Hospital Stay | 37.50 Days | Standard Deviation 34.537 |
| Retosiban | Length of Neonatal Hospital Stay | 26.05 Days | Standard Deviation 32.689 |
Secondary
Length of Stay Following Readmission to Hospital
Newborn hospital readmission following hospitalization for birth was collected from the newborn's medical records. Length of stay in hospital following readmission is presented for neonates.
Time frame: Up to 28 days after EDD (40 0/7 weeks gestation)
Population: Neonatal Safety Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Length of Stay Following Readmission to Hospital | 0 Days |
| Retosiban | Length of Stay Following Readmission to Hospital | 0 Days |
Secondary
Length of Stay in Specialized Care Unit
Neonatal healthcare resource utilization was collected from review of medical records. The length of stay in a specialized care unit (NICU or ICU) has been presented for neonatal participants with admission to ICU or NICU.
Time frame: Up to 28 days post EDD (40 0/7 weeks gestation)
Population: Neonatal Safety Population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Length of Stay in Specialized Care Unit | 40.34 Days | Standard Deviation 35.475 |
| Retosiban | Length of Stay in Specialized Care Unit | 35.60 Days | Standard Deviation 35.308 |
Secondary
Maternal Length of Stay in Hospital
Details on maternal health care resource use (both for hospitalizations related to preterm labor not resulting in a delivery and hospitalizations related to preterm labor/normal labor resulting in a delivery) associated with an episode of preterm labor, preterm delivery and normal term delivery (\>= 37 weeks gestation) were collected from review of medical records. Length of hospital stay associated with hospital admission for preterm labor and normal term labor/term delivery is presented. One participant in the retosiban arm did not have hospitalization data; hence, was excluded from the analysis at delivery. Only participants with data available at the specified time points were analyzed (indicated by n=X) in category titles. NA indicates standard deviation could not be calculated as only one participant was analyzed.
Time frame: Up to 28 days post EDD (40 0/7 weeks gestation)
Population: Maternal Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Maternal Length of Stay in Hospital | Preterm labor; n=1, 0 | 2.642 Days | — |
| Placebo | Maternal Length of Stay in Hospital | Preterm delivery; n=9, 7 | 10.177 Days | Standard Deviation 11.9312 |
| Placebo | Maternal Length of Stay in Hospital | Normal term delivery; n=4, 2 | 3.719 Days | Standard Deviation 2.2309 |
| Retosiban | Maternal Length of Stay in Hospital | Preterm delivery; n=9, 7 | 13.583 Days | Standard Deviation 20.767 |
| Retosiban | Maternal Length of Stay in Hospital | Normal term delivery; n=4, 2 | 4.635 Days | Standard Deviation 2.7616 |
Secondary
Neonatal APGAR Scores
APGAR is a quick test to assess the health of new born children. The test is performed at 1 and 5 minutes after birth. APGAR scale is determined by evaluating the new born on five categories (appearance, pulse, grimace, activity and respiration) on a scale from zero to two, then summing up the five values obtained. APGAR score ranges from 0 to 10 where a score of 7 and above is normal. The mean and standard deviation of APGAR scores at one minute and at five minutes of birth has been presented.
Time frame: Up to 5 minutes after birth
Population: Neonatal ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Neonatal APGAR Scores | one minute at birth | 7.3 Score on APGAR scale | Standard Deviation 1.8 |
| Placebo | Neonatal APGAR Scores | five minutes at birth | 8.5 Score on APGAR scale | Standard Deviation 1.05 |
| Retosiban | Neonatal APGAR Scores | one minute at birth | 7.5 Score on APGAR scale | Standard Deviation 1.78 |
| Retosiban | Neonatal APGAR Scores | five minutes at birth | 8.7 Score on APGAR scale | Standard Deviation 1.06 |
Secondary
Number of Fetal Participants With AEs and SAEs Prior to Delivery
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the other outcomes described before; is associated with liver injury and impaired liver function. Fetal AEs and SAEs included the adverse events that were experienced by the fetus prior to delivery. The number of fetal participants who experienced at least one AE and one SAE has been presented.
Time frame: Up to 17 weeks post-infusion
Population: Maternal Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Fetal Participants With AEs and SAEs Prior to Delivery | AE | 3 Participants |
| Placebo | Number of Fetal Participants With AEs and SAEs Prior to Delivery | SAE | 0 Participants |
| Retosiban | Number of Fetal Participants With AEs and SAEs Prior to Delivery | AE | 5 Participants |
| Retosiban | Number of Fetal Participants With AEs and SAEs Prior to Delivery | SAE | 1 Participants |
Secondary
Number of Maternal Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that mey require medical or surgical intervention to prevent one of the other outcomes described before; is associated with liver injury and impaired liver function. Maternal Safety Population comprised of all mothers randomly assigned to treatment who have been exposed to study treatment. The number of maternal participants who experienced at least one AE and one SAE has been presented.
Time frame: Up to 6 weeks after delivery
Population: Maternal Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Maternal Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 6 Participants |
| Placebo | Number of Maternal Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Retosiban | Number of Maternal Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 6 Participants |
| Retosiban | Number of Maternal Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
Secondary
Number of Maternal Participants With AEs of Special Interest (AESI).
Maternal AESI included: maternal death; chorioamnionitis and its complications (clinical chorioamnionitis, preterm premature rupture of membranes, endomyometritis, wound infection, pelvic abscess, bacteremia, septic shock, disseminated intravascular coagulation, and adult RDS); placental abruption; postpartum hemorrhage - postpartum hemorrhage and/or retained placenta and pulmonary edema. The number of participants with at least one AESI has been presented.
Time frame: Up to 6 weeks post-delivery
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Maternal Participants With AEs of Special Interest (AESI). | 0 Participants |
| Retosiban | Number of Maternal Participants With AEs of Special Interest (AESI). | 1 Participants |
Secondary
Number of Maternal Participants With a Score of 12 or Higher on the Edinburgh Postnatal Depression Scale (EPDS)
The effect of preterm birth on maternal health status was assessed using the EPDS. The EPDS is a 10-item self-reported assessment of depression, validated for administration during both the antenatal and the post-natal periods. Items are rated on a 4-point variable Likert scale, ranging from 0 to 3. The total score was calculated by adding individual scores for each item and ranged from 0 to 30. A score of less than 8 indicates depression not likely; score of 9 to 11 indicates possible depression and a score of more than 12 indicates an increased probability of depression. Maternal participants were required to complete the EPDS at the maternal follow-up assessment 6 weeks post-delivery.
Time frame: Up to 6 weeks post delivery
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Maternal Participants With a Score of 12 or Higher on the Edinburgh Postnatal Depression Scale (EPDS) | 2 Participants |
| Retosiban | Number of Maternal Participants With a Score of 12 or Higher on the Edinburgh Postnatal Depression Scale (EPDS) | 0 Participants |
Secondary
Number of Maternal Participants With Disease Related AEs (DRE)
Maternal DREs included: signs and symptoms of labor discomfort (example, cramping, backache, muscle aches, nausea); subsequent episodes of preterm labor and hospitalization for delivery. The number of participants with at least one DRE has been presented.
Time frame: Up to 6 weeks post-delivery
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Maternal Participants With Disease Related AEs (DRE) | 0 Participants |
| Retosiban | Number of Maternal Participants With Disease Related AEs (DRE) | 1 Participants |
Secondary
Number of Neonatal Participants With Admission to a Particular Hospital Unit
Neonatal healthcare resource utilization was collected from review of medical records. The number of neonatal participants who were admitted to a particular hospital unit that is, level III (or higher) intensive neonatal care (NICU), Intensive care unit (ICU), general ward, Level I - Basic Neonatal care, Well born nursery (SCBU) and Level II-Special Care Newborn nursery high dependency (NHDU) has been summarized. Neonatal Safety Population consisted of neonates whose mothers received study treatment.
Time frame: Up to 28 days post EDD (40 0/7 weeks gestation)
Population: Neonatal Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Intensive care unit | 0 Participants |
| Placebo | Number of Neonatal Participants With Admission to a Particular Hospital Unit | General Ward | 2 Participants |
| Placebo | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Level II-Special Care NHDU | 0 Participants |
| Placebo | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Missing | 1 Participants |
| Placebo | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Multiple ward type | 5 Participants |
| Placebo | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Level III (or higher) NICU | 5 Participants |
| Retosiban | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Multiple ward type | 0 Participants |
| Retosiban | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Intensive care unit | 1 Participants |
| Retosiban | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Missing | 0 Participants |
| Retosiban | Number of Neonatal Participants With Admission to a Particular Hospital Unit | General Ward | 2 Participants |
| Retosiban | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Level III (or higher) NICU | 6 Participants |
| Retosiban | Number of Neonatal Participants With Admission to a Particular Hospital Unit | Level II-Special Care NHDU | 1 Participants |
Secondary
Number of Neonatal Participants With AEs and SAEs
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the other outcomes described before; is associated with liver injury and impaired liver function. The number of participants who experienced at least one AE and one SAE has been presented. Neonatal Safety Population consisted of neonates whose mothers received randomized treatment.
Time frame: Up to 28 days after the EDD of 40 weeks gestation
Population: Neonatal Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Neonatal Participants With AEs and SAEs | AEs | 8 Participants |
| Placebo | Number of Neonatal Participants With AEs and SAEs | SAEs | 3 Participants |
| Retosiban | Number of Neonatal Participants With AEs and SAEs | AEs | 7 Participants |
| Retosiban | Number of Neonatal Participants With AEs and SAEs | SAEs | 5 Participants |
Secondary
Number of Neonatal Participants With AESI
Neonatal AESI included: Neonatal death; Asphyxia; Infections (early onset neonatal sepsis, septic shock, pneumonia, meningitis); RDS; Hypotension; IVH/periventricular leukomalacia; Bronchopulmonary dysplasia; Neonatal acidosis; Hyperbilirubinemia; Necrotizing enterocolitis; and Hypoxic ischemic encephalopathy. The number of neonatal participants who experienced at least one AESI has been presented.
Time frame: Up to 28 days after EDD of 40 weeks gestation
Population: Neonatal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Neonatal Participants With AESI | 8 Participants |
| Retosiban | Number of Neonatal Participants With AESI | 5 Participants |
Secondary
Number of Neonatal Participants With DRE
The disease related neonatal events occurring in Infants born prior to 37 completed weeks included: apnea (severe), respiratory failure due to fatigue, hypoxia, or air leak from alveolar injury, patent ductus arteriosus, bradycardia, ventriculomegaly, cerebellar hemorrhage, hydrocephalus other than congenital, gastroesophageal reflux, aspiration pneumonia, anemia, retinopathy of prematurity (all stages), hearing disorder, temperature instability and hypoglycemia. The number of participants with at least one DRE has been presented.
Time frame: Up to 28 days after EDD of 40 weeks gestation
Population: Neonatal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Neonatal Participants With DRE | 4 Participants |
| Retosiban | Number of Neonatal Participants With DRE | 2 Participants |
Secondary
Number of Neonates With Any of the Co-primary Composite Neonatal Morbidity and Mortality, Excluding RDS
The neonatal composite endpoint was determined from review of medical records and included the following components: fetal or neonatal death, RDS, bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis based on positive blood culture with clinical features of sepsis, meningitis based on positive results for cerebrospinal fluid culture performed as part of infection workup, retinopathy of prematurity, IVH, white matter injury and cerebellar hemorrhage. The number of neonates with any co-primary composite neonatal morbidity and mortality component, excluding RDS has been presented.
Time frame: Up to 28 weeks after EDD (40 weeks gestation)
Population: Neonatal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Neonates With Any of the Co-primary Composite Neonatal Morbidity and Mortality, Excluding RDS | 3 Participants |
| Retosiban | Number of Neonates With Any of the Co-primary Composite Neonatal Morbidity and Mortality, Excluding RDS | 0 Participants |
Secondary
Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality
The neonatal composite endpoint was determined from review of medical records and included the following components: fetal or neonatal death, RDS, bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis based on positive blood culture with clinical features of sepsis, meningitis based on positive results for cerebrospinal fluid culture performed as part of infection workup, retinopathy of prematurity, IVH, white matter injury and cerebellar hemorrhage. The number of neonates with each individual component of the composite component has been presented.
Time frame: Up to 28 days after the EDD of 40 0/7 weeks
Population: Neonatal ITT Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Bronchopulmonary dysplasia | 3 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Meningitis | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | RDS | 3 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Retinopathy of prematurity | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Necrotizing enterocolitis or Isolated Perforation | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | IVH | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Neonatal Death | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | White Matter Injury | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Sepsis | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Cerebellar Hemorrhage | 0 Participants |
| Placebo | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Fetal Death | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Cerebellar Hemorrhage | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Fetal Death | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Neonatal Death | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | RDS | 2 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Bronchopulmonary dysplasia | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Necrotizing enterocolitis or Isolated Perforation | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Sepsis | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Meningitis | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | Retinopathy of prematurity | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | IVH | 0 Participants |
| Retosiban | Number of Neonates With Each Individual Component of the Composite Neonatal Morbidity and Mortality | White Matter Injury | 0 Participants |
Secondary
Number of Newborn Participants With Hospital Readmission
Newborn hospital readmission following hospitalization for birth was collected from the newborn's medical records. The number of newborn participants who had readmission to hospital is presented.
Time frame: Up to 28 days of EDD (40 0/7 weeks gestation)
Population: Neonatal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Newborn Participants With Hospital Readmission | 0 Participants |
| Retosiban | Number of Newborn Participants With Hospital Readmission | 0 Participants |
Secondary
Number of Participants Admitted to Particular Hospital Unit
Maternal healthcare resource utilization associated with an episode of preterm labor, preterm delivery and normal term delivery were collected from the review of medical records. The number of participants who were admitted to a particular hospital unit has been presented.
Time frame: Up to 28 days post EDD (40 0/7 weeks gestation)
Population: Maternal Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants Admitted to Particular Hospital Unit | General ward | 9 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Private/Semi-private room | 3 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Labor and delivery | 2 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Labor and delivery to post-partum | 0 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Post-partum | 0 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Ward not specified | 0 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Antenatal ward | 0 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Postnatal ward | 0 Participants |
| Placebo | Number of Participants Admitted to Particular Hospital Unit | Labor ward | 0 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Post-partum | 1 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | General ward | 2 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Antenatal ward | 1 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Private/Semi-private room | 2 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Ward not specified | 1 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Labor and delivery | 3 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Labor ward | 1 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Labor and delivery to post-partum | 1 Participants |
| Retosiban | Number of Participants Admitted to Particular Hospital Unit | Postnatal ward | 1 Participants |
Secondary
Number of Participants Who Discontinued Study Treatment Due to Clinical and Laboratory Toxicities
Number of maternal participants who discontinued study treatment due to clinical and laboratory toxicities is presented.
Time frame: Up to 48 hours post-infusion
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants Who Discontinued Study Treatment Due to Clinical and Laboratory Toxicities | 0 Participants |
| Retosiban | Number of Participants Who Discontinued Study Treatment Due to Clinical and Laboratory Toxicities | 0 Participants |
Secondary
Number of Participants Who Received Any Putative Tocolytic
A putative tocolytic medication was the medication administered for active preterm labor or as prevention of preterm labor and included calcium channel blockers, nonsteroidal anti-inflammatory drugs, or beta agonists, or magnesium sulfate doses that exceeded prespecified IV loading doses, infusion rates, or total duration of administration.
Time frame: Up to 17 weeks
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants Who Received Any Putative Tocolytic | 4 Participants |
| Retosiban | Number of Participants Who Received Any Putative Tocolytic | 1 Participants |
Secondary
Number of Participants With Ambulatory Surgery
Information regarding participants who had ambulatory surgery was collected from the newborn medical records. The number of neonatal participants with ambulatory surgery is presented.
Time frame: Up to 28 days post EDD (40 0/7 weeks gestation)
Population: Neonatal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Ambulatory Surgery | 0 Participants |
| Retosiban | Number of Participants With Ambulatory Surgery | 0 Participants |
Secondary
Number of Participants With Births <=7 Days From the First Study Treatment
The number of participants who delivered in less than or equal to 7 days from first dose of study treatment has been presented.
Time frame: Up to 7 days
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births <=7 Days From the First Study Treatment | 5 Participants |
| Retosiban | Number of Participants With Births <=7 Days From the First Study Treatment | 5 Participants |
Secondary
Number of Participants With Births at <=24 Hours From the First Study Treatment
The number of participants who delivered in less than or equal to 24 hours from first dose of study treatment has been presented.
Time frame: Up to 24 hours
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births at <=24 Hours From the First Study Treatment | 3 Participants |
| Retosiban | Number of Participants With Births at <=24 Hours From the First Study Treatment | 1 Participants |
Secondary
Number of Participants With Births at <=48 Hours From the First Study Treatment
The number of participants who delivered in less than or equal to 48 hours from first dose of study treatment has been presented.
Time frame: Up to 48 hours
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births at <=48 Hours From the First Study Treatment | 3 Participants |
| Retosiban | Number of Participants With Births at <=48 Hours From the First Study Treatment | 3 Participants |
Secondary
Number of Participants With Births at Term
Participants were considered to have delivered at term if the gestational age was \>=37 0/7. The number of participants who delivered at term, that is, 37 0/7 to 41 6/7 weeks gestation has been presented.
Time frame: Up to 17 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births at Term | 4 Participants |
| Retosiban | Number of Participants With Births at Term | 2 Participants |
Secondary
Number of Participants With Births Prior to 28 0/7 Weeks Gestation
The number of participants who delivered prior to 28 0/7 weeks gestation has been presented. Only those maternal participants who were randomized prior to 28 0/7 week's gestation and delivered were included.
Time frame: Up to 4 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births Prior to 28 0/7 Weeks Gestation | 2 Participants |
| Retosiban | Number of Participants With Births Prior to 28 0/7 Weeks Gestation | 1 Participants |
Secondary
Number of Participants With Births Prior to 32 0/7 Weeks Gestation
The number of participants who delivered prior to 32 0/7 weeks gestation has been presented. Only those maternal participants who were randomized prior to 32 0/7 week's gestation and delivered were included.
Time frame: Up to 8 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births Prior to 32 0/7 Weeks Gestation | 6 Participants |
| Retosiban | Number of Participants With Births Prior to 32 0/7 Weeks Gestation | 2 Participants |
Secondary
Number of Participants With Births Prior to 35 0/7 Weeks Gestation
The number of participants who delivered prior to 35 0/7 weeks gestation has been presented.
Time frame: Up to 11 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births Prior to 35 0/7 Weeks Gestation | 9 Participants |
| Retosiban | Number of Participants With Births Prior to 35 0/7 Weeks Gestation | 7 Participants |
Secondary
Number of Participants With Births Prior to 37 0/7 Weeks Gestation
Gestational age at birth (weeks) is defined as the gestational age when the baby is born. Participants were considered to have delivered prior to 37 0/7 weeks, that is preterm, if the gestational age at birth is less than 37 0/7 weeks. The number of participants who delivered prior to 37 0/7 weeks gestation has been presented.
Time frame: Up to 13 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Births Prior to 37 0/7 Weeks Gestation | 9 Participants |
| Retosiban | Number of Participants With Births Prior to 37 0/7 Weeks Gestation | 8 Participants |
Secondary
Number of Participants With Different Modes of Transportation to Hospital
The means by which the maternal participants were transported to the hospital i.e. ground ambulance/emergency vehicle (gr. amb/emer. veh), air ambulance, family member or other means were obtained from the review of medical records. The number of maternal participants with the corresponding mode of transportation is presented for preterm labor visit and delivery visit. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles).
Time frame: Up to 28 days post EDD (40 0/7 weeks gestation)
Population: Maternal Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor; <24 hour stay;other; n=1, 0 | 0 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor; air ambulance; n=1, 0 | 0 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor; family member; n=1, 0 | 1 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor; other; n=1, 0 | 0 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Delivery; gr. amb/emer. veh; n=5, 5 | 2 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor;<24 hour stay;gr. amb/emer.veh;n=1,0 | 0 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor; <24 hour stay;air ambulance; n=1, 0 | 0 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor; <24 hour stay;family member; n=1, 0 | 1 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Preterm labor; gr. amb/emer. veh; n=1, 0 | 0 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Delivery; air ambulance; n=5, 5 | 0 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Delivery; family member; n=5, 5 | 3 Participants |
| Placebo | Number of Participants With Different Modes of Transportation to Hospital | Delivery; other; n=5, 5 | 0 Participants |
| Retosiban | Number of Participants With Different Modes of Transportation to Hospital | Delivery; gr. amb/emer. veh; n=5, 5 | 1 Participants |
| Retosiban | Number of Participants With Different Modes of Transportation to Hospital | Delivery; family member; n=5, 5 | 3 Participants |
| Retosiban | Number of Participants With Different Modes of Transportation to Hospital | Delivery; air ambulance; n=5, 5 | 0 Participants |
| Retosiban | Number of Participants With Different Modes of Transportation to Hospital | Delivery; other; n=5, 5 | 1 Participants |
Secondary
Number of Participants With Fetal Acidosis
The number of participants with fetal acidosis is presented.
Time frame: Up to 16 weeks
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Fetal Acidosis | 0 Participants |
| Retosiban | Number of Participants With Fetal Acidosis | 0 Participants |
Secondary
Number of Participants With Fetal AESI
Fetal AESI included: intrauterine fetal demise; category II or III fetal heart rate tracing; and fetal inflammatory response syndrome characterized by cord blood interleukin-6 \>11 picogram per milliliter (pg/mL), funisitis, or chorionic vasculitis. The number of participants who experienced at least one AESI has been presented.
Time frame: Up to 17 weeks
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Fetal AESI | 3 Participants |
| Retosiban | Number of Participants With Fetal AESI | 5 Participants |
Secondary
Number of Participants With Hospital Admissions Related to Preterm Labor and Preterm Delivery
Maternal healthcare resource utilization associated with an episode of preterm labor and preterm delivery were collected from the review of medical records. One participant in the retosiban arm did not have hospitalization data; hence, was excluded from the analysis at delivery. The number of participants who had hospital admission for preterm labor and preterm delivery has been presented. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
Time frame: Up to 28 days after EDD (40 0/7 weeks of gestation)
Population: Maternal Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Hospital Admissions Related to Preterm Labor and Preterm Delivery | Preterm labor; n=13, 10 | 1 Participants |
| Placebo | Number of Participants With Hospital Admissions Related to Preterm Labor and Preterm Delivery | Preterm delivery; n=13, 9 | 9 Participants |
| Retosiban | Number of Participants With Hospital Admissions Related to Preterm Labor and Preterm Delivery | Preterm labor; n=13, 10 | 0 Participants |
| Retosiban | Number of Participants With Hospital Admissions Related to Preterm Labor and Preterm Delivery | Preterm delivery; n=13, 9 | 7 Participants |
Secondary
Number of Participants With Subsequent Preterm Labor
The participants who had not delivered after 48 hours post-infusion were contacted to determine if they had delivered or experienced any subsequent episodes of preterm labor. A subsequent episode of preterm labor was only recorded if the participant reported it to the Principal Investigator during one of the telephone follow-up calls but did not then go on to immediately deliver. However, if labor started and led to immediate delivery, then the only data collected would be the pre-specified delivery data and thus would not be counted as a subsequent episode of preterm labor. The number of participants who had a subsequent episode of preterm labor after administration of the study treatment has been presented. Maternal Safety Population comprised of all maternal participants randomly assigned to treatment who have been exposed to study treatment.
Time frame: Up to 11 weeks
Population: Maternal Safety Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Subsequent Preterm Labor | 1 Participants |
| Retosiban | Number of Participants With Subsequent Preterm Labor | 1 Participants |
Secondary
Retosiban Clearance
Maternal blood samples were collected at the indicated time points for pharmacokinetic analysis. Data is a combined data set. Data is presented for 10 participants from retosiban arm of study 200719 (NCT02377466) and 43 participants from retosiban arm of study 200721 (NCT02292771).
Time frame: Day 1 (2 to 4 hours, 10 to 14 hours) and Day 2 (22 to 26 hours, and 48 to 54 hours) post-infusion
Population: Maternal Safety Population. Data is a combined data set. Data is presented for 10 participants from retosiban arm of study 200719 (NCT02377466) and 43 participants from retosiban arm of study 200721 (NCT02292771).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Retosiban Clearance | 83.4 Liters per hour | Geometric Coefficient of Variation 5.25 |
Secondary
Time to Delivery
The time to delivery was calculated as the days between the delivery and start time of the study treatment infusion using the formula: Time to delivery (days) = (date and time of delivery minus date and time of start of infusion) divided by (24 multiplied by 60). The mean number of days to delivery along with standard deviation has been presented.
Time frame: Up to 17 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Time to Delivery | 16.32 Days | Standard Deviation 18.595 |
| Retosiban | Time to Delivery | 19.18 Days | Standard Deviation 22.77 |
Secondary
Time to Treatment Failure
Treatment failure is defined as the administration of any putative tocolytic medication for treatment of preterm labor or as prophylaxis of preterm labor. Time to treatment failure is the number of days from the first dose of study treatment until treatment failure. The mean number of days to delivery or treatment failure along with standard deviation has been presented. Only those maternal participants with treatment failure were included in the analysis. NA indicates standard deviation could not be calculated as only one participant was analyzed.
Time frame: Up to 17 weeks
Population: Maternal ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Time to Treatment Failure | 1.141 Days | Standard Deviation 1.4307 |
| Retosiban | Time to Treatment Failure | 0.899 Days | — |
Secondary
Volume of Distribution of Retosiban
Maternal blood samples were collected at the indicated time points for pharmacokinetic analysis. Data is a combined data set. Data is presented for 10 participants from retosiban arm of study 200719 (NCT02377466) and 43 participants from retosiban arm of study 200721 (NCT02292771).
Time frame: Day 1 (2 to 4 hours, 10 to 14 hours) and Day 2 (22 to 26 hours, and 48 to 54 hours) post-infusion
Population: Maternal Safety Population. Data is a combined data set. Data is presented for 10 participants from retosiban arm of study 200719 (NCT02377466) and 43 participants from retosiban arm of study 200721 (NCT02292771).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Volume of Distribution of Retosiban | 68.6 Liters | Geometric Coefficient of Variation 109 |
Secondary
Weight of Neonates
The weight of neonates was obtained from the neonate birth record. The mean weight of neonates and standard deviation has been presented.
Time frame: Up to 17 weeks
Population: Neonatal ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Weight of Neonates | 2015.0 grams (g) | Standard Deviation 805.67 |
| Retosiban | Weight of Neonates | 2121.2 grams (g) | Standard Deviation 681.31 |